HOME >> MEDICINE >> NEWS
Better survival seen for early breast cancer patients switched from tamoxifen to Aromasin

ATLANTA, June 3, 2006 New data from the Intergroup Exemestane Study (IES) showed for the first time today that hormone sensitive postmenopausal early breast cancer patients who switched to Aromasin after 2 to 3 years of tamoxifen were 17% more likely to be alive and were 25% less likely to have their cancer return than patients who continued on tamoxifen for a full 5 years of therapy.

"Exemestane is the only anti-hormonal therapy that has been shown to demonstrate improved overall survival over tamoxifen alone," said Lead Investigator Professor Charles Coombes, director of cancer medicine, Imperial College, London. These significant survival benefits were seen in patients who are considered hormone sensitive, which represents 97% of the study population. Although not statistically significant in the intent to treat population, 15% of patients taking Aromasin were more likely to be alive versus those that continued on tamoxifen. These new findings were based on nearly 5 years of follow-up after randomization in the IES trial. IES was a large randomized double blind multinational trial of postmenopausal women with early breast cancer which was designed to compare the clinical benefits of switching 2352 patients to Aromasin after 2 to 3 years of tamoxifen versus continuing 2372 patients on tamoxifen for a full 5 years of therapy. The 5 year follow-up time includes a period of observation lasting over 2 years after completion of all treatment.

Earlier results of the IES trial, which led to US FDA and European regulatory approvals of Aromasin for treatment of early breast cancer, found that postmenopausal hormone receptor positive patients, which represented 85% of all patients in the trial, who switched to Aromasin reduced their risk of breast cancer recurring by 35% versus patients who stayed on tamoxifen for 5 years. At the earlier time point, a difference in overall survival had not been seen.

Breast cancer is one of the most comm
'"/>


3-Jun-2006


Page: 1 2 3

Related medicine news :

1. Better mobility keeps seniors healthier
2. Better insight into brain anatomical structures
3. Better health twice as likely for nonsmokers who live and work with smoking restrictions
4. Better designed roadway intersections can boost older drivers performance
5. Better strategies for osteoporosis prevention and therapy
6. Better review of new technology is needed to reduce health costs
7. Better training needed to reduce emergency caesareans
8. Better after-school snack choices boost nutrition for low-income kids, UC Davis research confirms
9. Outcomes of patients in trials; Better blood pressure treatment; Snake bites, and more
10. Better regulation needed for ethical research in Africa
11. Better procedures needed on care of prisoners in hospitals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... D.C., (PRWEB) , ... April 28, 2016 , ... ... systems, and the Campaign for Tobacco-Free Kids, a leading force in the fight ... promote federal, state and local policies that can help reduce tobacco use. The ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... Greener Hydroponics ... season. Smart pots are frequently used by professional organic farmers and nurseries according to ... order their supply of fabric pots. Our goal is to offer wholesale level pricing ...
(Date:4/28/2016)... , ... April 28, 2016 , ... In many parts ... principal determinant of childhood mortality. This is particularly true in underdeveloped parts of Africa ... the University of New England’s campus in Tangier, Morocco, will examine this global health ...
(Date:4/28/2016)... ... ... In 2011, TIME magazine named Herr the “Leader of the Bionic Age”, because ... physiology with electromechanics. He continues that work as Director of the Biomechatronics research group ... a leader in the field of prosthetic devices. , After a blizzard during a ...
(Date:4/28/2016)... ... April 28, 2016 , ... Horizon Blue Cross ... doctors and hospitals to make transformative changes in how health care is delivered ... this week in discussing breakthroughs in cellular medicine to treat disease. After accepting ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... plastic surgery products market is expected to grow at ... ,The growing adoption of laser in aesthetics is another ... Lasers are used to treat a broad range of ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
Breaking Medicine Technology:
Cached News: